The SUDx Dashboard helps providers address three critical payor priorities
Treatment-Resistant Patients
≈ 10% of patients who are resistant to standard interventions, allowing providers to allocate more cost–effective resources earlier in their treatment.
Over Utilization
≈ 70% of patients who stabilize in response to standard interventions, allowing for less frequent visits and toxicology testing.
Relapse-Prone Patients
≈ 20% of patients who are most likely to relapse, allowing providers to allocate the necessary resources when needed.
Case Study
One of SUDx’s customers is MATClinics, the largest outpatient provider of addiction treatment in Maryland. Serving a largely Medicaid patient population at eight locations throughout the state, it relies on SUDx for customizable toxicology testing, as well as proprietary analytics on the SUDx Dashboard, to improve both the efficacy of their care and the efficiency of their operations.
“Both the toxicology results and the Dashboard’s data analytics enable us to clarify where a patient is on their path to recovery, while estimating their adherence to treatment with a high degree of probability” said Dr. Enrique Oviedo, a triple board-certified psychiatrist specializing in addiction treatment who serves as the Chief Medical Officer for MATClinics.
“We can now tailor treatment resources to a patient’s needs in ways that we couldn’t before.”
In addition to operating a COLA-accredited lab, which is licensed by the State of Maryland and certified by CLIA, SUDx developed a Dashboard consisting of proprietary digital tools that identify the ≈ 10% of patients who are resistant to standard interventions, along with the ≈ 20% of patients who are likely to relapse.
“The opioid crisis has placed a demand on providers that’s difficult to overstate,” Dr. Oviedo said. “Having the best possible digital tools, including historic toxicology data, in the Dashboard has never been more important. "The SUDX Dashboard is an essential resource for any medical provider who treats substance use disorders."
“We can now tailor treatment resources to a patient’s needs in ways that we couldn’t before.”
In addition to operating a COLA-accredited lab, which is licensed by the State of Maryland and certified by CLIA, SUDx developed a Dashboard consisting of proprietary digital tools that identify the ≈ 10% of patients who are resistant to standard interventions, along with the ≈ 20% of patients who are likely to relapse.
“The opioid crisis has placed a demand on providers that’s difficult to overstate,” Dr. Oviedo said. “Having the best possible digital tools, including historic toxicology data, in the Dashboard has never been more important. "The SUDX Dashboard is an essential resource for any medical provider who treats substance use disorders."
